News for Insmed Incorporated (0JAV.L)

Insmed (INSM) will redeem all outstanding $569.5 million of 0.75% Convertible Senior Notes Due 2028. The redemption is scheduled for June 6, 2025, offer

Insmed's Phase 3 ASPEN study of brensocatib shows significant reduction in annualized pulmonary exacerbation rates. Brensocatib (INSM) demonstra

Insmed Incorporated (INSM) has announced encouraging outcomes from the phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis, w

PR NewswireBRIDGEWATER, N.J., April 23, 2025 ””Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and C

PR NewswireBRIDGEWATER, N.J., April 23, 2025 BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global bi

Insmed (INSM) to release Q1 2025 financial results on May 8, 2025. Conference call scheduled for 8:00 a.m. ET, accessible via phone or webcast. Repla

We recently published a list of 20 Stocks Insiders Were Selling In Q1 2025.

We recently published a list of 20 Stocks Insiders Were Selling In Q1 2025. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other stocks insiders were selling in Q1 2025. The broader market index rose 0.2% on Tuesday amid volatility as investors awaited clarity on President Trump’s tariff […]

PR NewswireBRIDGEWATER, N.J., March 25, 2025 ””New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires.

PR NewswireBRIDGEWATER, N.J., March 10, 2025 BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global bi

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

PR NewswireBRIDGEWATER, N.J., Feb. 24, 2025 ””FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025””BRID

Insmed Incorporated (NASDAQ:INSM) Q4 2024 Earnings Call February 20, 2025 8:00 AM ETCompany ParticipantsBryan Dunn - Investor RelationsWill Lewis - Chair...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion dollar market potential.

PR NewswireBRIDGEWATER, N.J., Feb. 7, 2025 BRIDGEWATER, N.J., Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopha

PR NewswireBRIDGEWATER, N.J., Jan. 10, 2025 --ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 20

PR NewswireBRIDGEWATER, N.J., Jan. 3, 2025 BRIDGEWATER, N.J., Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopha